A Clinical Prognostic Index for Assessing Patients aged >60 Being Considered for High‐Dose Therapy and Autologous Stem‐Cell Transplant in Relapsed or refractory High‐Grade Non‐Hodgkin Lymphoma

Newsletter

Latest newsletter: January 2022

Select newsletter to download

Top